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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) is a malignancy derived from epithelial cells lining the 
nasopharynx. The etiology of nasopharyngeal carcinoma is multifactorial. One of the risk factors is CYP2A6 gene 
polymorphism which causes nitrosamines are not metabolized, leading to DNA change that could trigger cancer. 
Objective: The purpose of this study is to know the association of CYP2A6 gene polymorphism and clinical 
stage of undifferentiated type of NPC. 
Method: This is a cross sectional analytic study. The sample in this study were 80 nasopharyngeal carcinoma 
patients whose treated in ENT-HN department of Sanglah General Hospital between 2017-2018. The collected data 
consist of subject’s characteristic and CYP2A6 gene polymorphisms identified by the PCR-RFLP technique. 
Result: The probability of CYP2A6 gene polymorphism in the undifferentiated type of NPC in the Balinese 
tribe is 3.125 times greater in advanced stage than early stage. Based on multivariate analysi s, there was a 
statistically significant association between CYP2A6 gene polymorphism and clinical stage of undifferentiated 
type NPC in Balinese with p value =0.0048 (p <0,05). 
Conclusion: There is association between CYP2A6 gene polymorphism and clinical stage of undifferentiated 
type NPC in Balinese tribe. 
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1. INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is the most common head and 
neck malignancy in the world and in Indonesia. The incidence of NPC 
in the world is 1.2/100,000 individuals per year with diverse 
distribution based on geography [1]. The incidence of NPC is almost 
evenly distributed in every region in Indonesia. In RSCM Jakarta, more 
than 100 cases were found in a year and based on data from the NPC 
patient register at the ENT outpatient clinic at Sanglah Hospital from 
September 2015 to September 2017 there were 265 NPC patients.  
The main cause of NPC still unknown. The cause i s multifactorial 
and is often related to Epstein-Barr virus infection, genetic, and the 
environment factors [2]. Genetic susceptibility as a predisposing factor 
for NPC is based on the fact that there are many sufferers from the 
Chinese race, Mongoloid race, including the nations of Asia, especially 
Southeast Asia, which are still classified as Malay.  
One of the genes associated with NPC is the CYP2A6 gene. This 
gene codes for the CYP2A6 enzyme, which is a first phase enzyme that 
plays a role in the metabolism of nicotine and some nitrosamine 
compounds found in tobacco. Polymorphisms in genes that encode the 
CYP2A6 enzyme are associated with individual metabolic variations in 
a xenobiotic [3]. CYP2A6 gene polymorphism is found around 1% in 
Caucasian race and its frequency is quite high, reaching 15-25% in 
Asian nations. Some mutations in CYP2A6 will reduce enzymatic 
activity and even eliminate enzyme activity. CYP2A6 gene 
polymorphism as one of the biomarkers in NPC is interesting to study 
because there is a strong association between CYP2A6 gene 
polymorphisms and the incidence of NPC. Research on CYP2A6 
polymorphisms in people with NPC in Indonesia is still very little while 
in Bali has never been studied. The Balinese are still classified as a 
Malay family, where there are many NPC incidents.  
2. MATERIAL AND METHODS 
The research design used in this study is a cross-sectional design. 
The sample was selected by consecutive sampling until the required 
number of samples were met which meet the inclusion criteria. The 
inclusion criteria were new patients undergoing nasopharyngeal biopsy 
and histopathological examination at the Anatomy Pathology 
Laboratory of the Faculty of Medicine, Udayana University/Sanglah 
Hospital Denpasar and were diagnosed with undifferentiated type NPC, 
and were Balinese tribe. The subject were excluded from this study if 
they did not underwent biopsy in Sanglah Hospital or their biopsy 
preparations are unreadable, damaged and not found.  
The data was analyzed by univariate, bivariate, multivariate 
analysis. Univariate analysis was used to describe the subjects studied 
according to age, sex, clinical stage of undifferentiated type NPC, and 
CYP2A6 gene polymorphism. Bivariate analysis was used to determine 
the association of CYP2A6 gene polymorphism with clinical stage of 
undifferentiated type NPC in Balinese.  
3. RESULT 
This study is using 80 samples who meets inclusion criteria. 
Researcher use genomic DNA measurements obtained from isolation 
using the PCR (Polymerase Chain Reaction) technique, genomic DNA 
fragments that was analyzed can be increased in quantity by in vitro 
amplification in a short time using primary pairs of synthetic 
oligonucleotides that limit the area which will be reproduced. 
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Table 1. Distribution of Undifferentiated NPC based on the clinical stage  
Variable n=80 n% 
Clinical stage of undifferentiated NPC   
Stage I 0 0% 
Stage II 16 20% 
Stage III 5 6.25% 
Stage IV A 25 31.3% 
Stage IV B 34 42.5% 
Early stage 16 20% 
Advanced stage 64 80% 
Table 1 shows the distribution of undifferentiated NPC based on clinical 
stage were stage II as many as 15 patients (11.8%), stage III as many as 6 
patients (7.50%), stage IVA as many as 25 patients (31.3%), and stage IVB 
as many as 34 patients (42.5%). Distribution of early stage NPC patients 
was 16 patients (20%) and advanced stage 64 patients (80%). 
Table 2. The distribution of CYP2A6 gene genotype 
Genotype Group n=80 n% 
*1A/*1A 53 66.3% 
*1A/*non 1A 2 2.5% 
*non1A/*non1A 25 31.3% 
The most common genotypes found were wild type homozygous 
(*1A/*1A) as many as 52 patients (65%). The mutant heterozygote group 
(*1A/*non 1A) were 2 patients (2.5%) and the mutant homozygote group 
(*non1A/*non 1A) were 26 patients (32.5%). 
Table 3. The distribution of CYP2A6 gene genotype in clinical stage 
undifferentiated type NPC  
Clinical Stage *1A/*1A *1A/*non 1A *non1A/*non1A Total 
Early stage 14 (87.5%) 1 (6.3%) 1 (6.3%) 16 (100%) 
Advanced stage 39 (60.9%) 1 (1.6%) 24 (37.5%) 64 (100%) 
The most common distribution of genotypes in the early-stage NPC 
group was homozygous wild type (*1A/*1A) genotype, as many as 14 
patients (87.5%). The most common genotype of advanced stage group was 
wild type (*1A/*1A) as many as 39 patients (60.9%) 
Table 4. The distribution of CYP2A6 gene genotype  
Genotype Early stage Advanced stage 
CYP2A6 *1A/ CYP2A6 *1A  14 (87.5%) 39 (60.9%) 
CYP2A6 *1A/ CYP2A6 *1B 0 (0%) 0 (0%) 
CYP2A6 *1A/ CYP2A6 *4C  1 (6.3%) 1 (1.6%) 
CYP2A6*1B / CYP2A6*4C 0 (0%) 0 (0%) 
CYP2A6*1B / CYP2A6*1B 0 (0%) 0 (0%) 
CYP2A6*4C / CYP2A6*4C 1 (6.3%)  24 (37.5%) 
Total  16 (20%)  64 (80%) 
After obtaining the results of stage 1 RFLP, then samples with *non 1A 
mutant alleles were analyzed by stage 2 RFLP with the Bsu36I enzyme to 
distinguish *4C and *1B alleles. After the second phase of RFLP, the highest 
genotype of the undifferentiated type NPC in Balinese was *1A/*1A which 
was found in 53 samples (66.3%) while the mutant genotype group as many 
as 27 samples (33.8%). 
Table 5. The distribution of CYP2A6 mutant gene genotype 
Genotype 
Early stage 
n=16 
Advance stage 
n=64 
CYP2A6 *1A/ CYP2A6 *4C  1 (6.3 %) 1 (1.6 %) 
CYP2A6*4C / CYP2A6*4C 1 (6.3 %)  24 (37.5 %) 
This study only found allele mutants *1A/*4C and *4C/*4C. After the 
stage 1 RFLP examination which was later identified with stage 2 RFLP no 
other mutant alleles were found. 
Table 6. Comparison of CYP2A6 gene polymorphism in early and 
advanced stage of NPC patients  
Variable 
Polymorphism 
PR 95% CI P 
Found Not Found 
Advanced Stage 25 (39.1%) 39 (60.9%) 3.125 0.046 
Early Stage 2 (12.5%) 14 (87.5%)   
 
Based on the cross tabulation above, it was found there were 2 patients 
(12.5%) in the early stages, while in the advanced stage 25 patients (39.1%) 
had polymorphisms in the CYP2A6 gene allele. while there are as many as 
14 patients (87.5%) in the early stages and 39 patients (60.9%) in advanced 
stage who did not experience polymorphism in the CYP2A6 (wild type) 
gene. To find out the proportion comparison of CYP2A6 gene 
polymorphisms between advanced stage and early stage of undifferentiated 
type NPC in Balinese, chi square test was used and the value of p =0.046 (p 
<0.05) was obtained. So there is a statistically significant relationship. 
To find out the relationship between CYP2A6 gene polymorphism and 
clinical stage of undifferentiated type NPC in Balinese, a multivariate 
analysis with logistic regression test was performed. Selection of this test to 
rule out confounding factors such as age and sex in the analysis. In this 
study, a significant relationship was found between the CYP2A6 gene 
polymorphism and the clinical stage of undifferentiated type NPC Bali, with 
a p value =0.048 (p <0.05) 
4. DISCUSSION 
The distribution of subjects based on the clinical stage of the 
undifferentiated type NPC in Balinese were 16 patients (20%) in early stage 
and 64 patients (80%) in advanced stage. This is consistent with research by 
Cheng et al (2014) that found 39.1% of patients in early-stage and 60.9% of 
patients in advanced stage NPC. This shows that patients usually came in 
advance stages. The diagnosis of NPC is often made too late because the 
location of the nasopharynx is hidden behind the nasal cavity and under the 
base of the skull so NPC patients generally come for treatment at an 
advanced stage [4,5]. 
CYP2A6 is a first phase enzyme which plays a role in the metabolism of 
nicotine and some nitrosamine compounds found in tobacco. NNK and NNN 
are among the major toxic components found in tobacco cigarettes [6]. 
Polymorphisms in genes that encode the CYP2A6 enzyme are 
associated with variations in the metabolic activity of an individual against a 
xenobiotic therefore two subgroups with different metabolic abilities will be 
found in the population. Subgroups with less metabolic ability are referred to as 
poor metabolizers or PM phenotypes, while subgroups with normal metabolic 
ability are referred to as extensive metabolizers or EM phenotypes [7]. 
The CYP2A6 gene polymorphism was found to be quite high in Asian 
nations. The proportion based on the CYP2A6 gene allele polymorphism in 
the undifferentiated type of NPC patient in Balinese was the mutant genotype 
group as many as 27 samples (33.8%). The mutant genotypes group consisted 
of heterozygotes mutants (*1A/*non 1A) in 2 patients (2.5%) and 
homozygotes mutant (*non 1A/*non 1A) groups of 25 patients (31.3%). 
This study only found allele mutants *1A/*4C and *4C/*4C. After the 
phase I RFLP examination which was later identified with phase II RFLP, 
no other mutant alleles were found. This is in accordance with research 
conducted by Savitri (2014) where the most polymorphisms found in 
patients with NPC were on allele 4*C of 24 subjects (25%) [8]. 
In general, the genotype frequency of the CYP2A6 gene was highly 
dependent on ethnic or ethnic background. For example, the frequency of 
the CYP2A6 *4/*4 genotype is 3.2-5% in the Japanese population, 1.9% in 
the Korean population and 1.5-3.0% in the Chinese population and 0% in 
the Caucasian. In contrast, genotypes CYP2A6 *2/*2 and CYP2A6 *3/*3 
are often found in Caucasian than in Asian. Therefore, the CYP2A6 *4/*4 
genotype is often becoming a field of study particularly in Asia [9]. 
Research by Tiwawech et al. (2006) in a Thai population revealed that 
individuals with *1B and/or *4C mutant alleles were twice as likely to suffer 
from NPC as wild-type allele individuals [9]. Wassenaar et al. (2011) also 
stated the same thing that CYP2A6 gene polymorphisms increase the risk 
of lung cancer. While the research of Cao et al. (2011) concluded that there 
was no significant relationship between CYP2A6 polymorphisms compared 
to wild type individuals with NPC and other types of cancer [9]. 
CYP2A6 gene polymorphisms are associated with individual metabolic 
variations of a xenobiotic. Variation of the CYP2A6 gene allele not only 
causes variations in genotype level, but also in phenotype level in the form 
of increasing or decreasing and even resulting in the loss of enzyme activity 
altogether (null mutation) as in the CYP2A6 *4 allele [10]. CYP2A6 *4C 
gene polymorphism is a type of base number variation genetic 
polymorphism (copy number variation) involving a broader segment of 
DNA in the form of a comprehensive deletion of the CYP2A6 gene that 
causes a complete loss of enzyme activity (null mutation) [10]. 
A defect in the CYP2A6 gene will increase the risk of cancer, this is related 
to the first-pass clearance of nitrosamines as a carcinogen. CYP2A6 has an 
important role in the pathway of nitrosamine metabolism in the liver. Loss of this 
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enzyme activity due to total deletion will inhibit the first pass clearance of 
nitrosamines so that the level of this carcinogen increases in other organs (post-
liver) such as the esophagus and airway. The defects on CPY2A6 in increasing 
cancer risk mainly occurs in tobacco induced cancer. Individuals with complete 
deletion of the CYP2A6 gene have lower levels of cotinine in their urine, which 
is only 15% compared to individuals without the CYP2A6 gene polymorphism 
who consume cigarettes in the same amount and time span. This shows that the 
level of pro-carcinogen in the body is still very high therefore the risk of smokers 
is very high for malignancy [6]. 
Based on the cross tabulation in table 6, in the early stages of the 
undifferentiated type of NPC there were 2 subjects (7.4%) and 25 subjects 
(92.6%) in the advanced stage had polymorphisms in the CYP2A6 gene 
allele. In the early stages as many as 14 patients (26.4%) and in the advanced 
stage as many as 39 (73.6%) who did not experience polymorphism in the 
CYP2A6 gene (wild type). In this study, a total of 27 patients (33.8%) had 
CYP2A6 gene polymorphisms. To find the comparison of the proportion 
CYP2A6 gene polymorphisms between the advanced stage and the early 
stage of undifferentiated NPC type in Balinese, the chi square test was used 
and the proportion of CYP2A6 gene polymorphisms in patients with 
advanced stage undifferentiated type NPC was higher than the initial stage, 
which was 3.125 times with a p value =0.046 (p <0.05). 
To find the relationship between CYP2A6 gene polymorphism and 
clinical stage of undifferentiated type NPC in Balinese, a multivariate 
analysis with logistic regression test was performed. Selection of this test to 
rule out confounding factors such as age and sex in the analysis. A 
significant relationship was found between the CYP2A6 gene 
polymorphism and the clinical stage of undifferentiated type NPC in 
Balinese, with a p value =0.048 (p <0.05). Age and gender did not show a 
significant relationship with the clinical stage of NPC sufferers. 
Examination of the CYP2A6 gene polymorphism can be used as one of 
the supporting modalities in assessing tumor growth, progression, and 
prognosis of the disease. This is consistent with Ren's (2018) regarding the 
relationship of CYP2A6 gene defects with overall survival and recurrence 
free survival in hepatocellular carcinoma found that CYP2A6 gene defects 
are associated with worse overall survival and recurrence free survival in 
patients with hepatocellular carcinoma. In also found CYP2A6 gene 
polymorphisms associated with metastases that include vascular invasion, 
porta major venous invasion, intrahepatic spread, and elevated levels of 
AFP. [11,12]  Research by Tiwawech et al. showed relationship between the 
CYP2A6 gene polymorphism and the clinical stage of NPC patients [9,13]. 
The etiology of NPC is often associated with the presence of Epstein-
Barr virus infection, genetic, and the environment factors (exposure to 
carcinogens). Gene polymorphisms related to carcinogenic metabolism are 
one of the risk factors for NPC. One of them is the cytochrome P450 gene 
family 2 subfamily A polypeptide 6 (CYP2A6) which codes for the 
CYP2A6 enzyme for activation of pro-carcinogens [14,15]. 
5. CONCLUSION 
The proportion of CYP2A6 gene polymorphisms in patients with 
advanced stage of undifferentiated type NPC was higher than the early stage, 
which was 3.125 times with p =0.046 (p <0.05). Based on a multivariate 
analysis test, a statistically significant relationship was found between the 
polymorphism of the CYP2A6 gene and the clinical stage of 
undifferentiated type NPC in Balinese, with a p value =0.048 (p <0.05). 
 
ADVICE 
Optimizing data distribution nasopharyngeal carcinoma patients at the Ear 
Nose Throat-Head Neck Surgery Bangli Hospital. Further research needs to be 
conducted with a sample of more as a reference to determine the distribution of 
patients with nasopharyngeal carcinoma development in Indonesia. 
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